Zimbabwe has turned down a major US health deal valued at $367m (272 million pounds) spanning five years because of Washington's insistence on sensitive information.
This move came to light after a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the agreement was "lopsided".
An official spokesman later stated that the US was seeking genetic material for scientific study and commercial purposes while was not willing to guarantee the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued dialogue to find a agreement acceptable to all parties so the country's critical HIV programme can be sustained.
Wider Background
This rejection follows a comparable case in Kenya, where a court blocked a related health funding agreement following legal challenges were filed about the security of citizens' medical information.
After returning to office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had administered assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance transparency and responsibility.
As per reports, Sixteen African countries have so far signed similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Put simply, our country would provide the basic resources for scientific discovery with no certainty that the final treatments would be available to our people should a new pandemic emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining systems already established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This mechanism is intended to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to continued dialogue with our US partners on how subsequent co-operation could be arranged in a manner that honours the independence and dignity of both nations."
Health Experts Response
A leading public health body stated it recognised the official position, but suggested that talks should continue since a large portion of the country's Aids initiatives were funded by international support.
"In cases where technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," it added.
The halted deal emphasises the continuing tensions between receiving crucial foreign assistance and protecting national sovereignty in an ever more interconnected world.